A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia

Blood

Volumn 118, Issue 14, 2011, Pages 3832-3841

  Lee, Je Hwan ^a   Joo, Young Don ^b   Kim, Hawk ^c   Bae, Sung Hwa ^d   Kim, Min Kyoung ^e   Zang, Dae Young ^f   Lee, Jung Lim ^g   Lee, Gyeong Won ^h   Lee, Jung Hee ^a   Park, Jae Hoo ^c   Kim, Dae Young ^a   Lee, Won Sik ^b   Ryoo, Hun Mo ^d   Hyun, Myung Soo ^e   Kim, Hyo Jung ^f   Min, Young Joo ^c   Jang, Yae Eun ⁱ   Lee, Kyoo Hyung ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Ulsan University College of Medicine   (South Korea)

^d Catholic University of Daegu   (South Korea)

^e Young Nam University Hospital   (South Korea)

^f Hallym University   (South Korea)

^g Daegu Fatima Hospital   (South Korea)

^h Gyeongsang National University   (South Korea)

ⁱ NONE   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLEEDING DISORDER; BLOOD CLOTTING DISORDER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE COMPARISON; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; EVENT FREE SURVIVAL; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HEPATITIS; HUMAN; INFECTION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; SKIN DISEASE;

EID: 80053637528     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-361410     Document Type: Article

References (24)

1. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
2. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894- 1907. (Pubitemid 44794525)
3. Preisler H, Davis RB, Kirshner J, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study. Blood. 1987;69(5):1441-1449. (Pubitemid 17085306)
4. Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood. 1981;58(6):1203-1212. (Pubitemid 12251149)
5. Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982;60(2):454-462. (Pubitemid 12048693)
6. Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia: Australian Leukemia Study Group. Blood. 1990;75(1):27-32. (Pubitemid 20031485)
7. Lowenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364(11):1027-1036.
8. Schiller G, Gajewski J, Nimer S, et al. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. Br J Haematol. 1992;81(2):170-177.
9. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88(8):2841-2851. (Pubitemid 26357364)
10. Hewlett J, Kopecky KJ, Head D, et al. A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): a Southwest Oncology Group study. Leukemia. 1995;9(4):562-569.
11. Usui N, Dobashi N, Kobayashi T, et al. Role of daunorubicin in the induction therapy for adult acute myeloid leukemia. J Clin Oncol. 1998;16(6):2086-2092. (Pubitemid 28265045)
12. Appelbaum FR, Dahlberg S, Thomas ED, et al. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intern Med. 1984;101(5):581-588. (Pubitemid 15223292)
13. Todeschini G. High-dose anthracycline induction in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001;15(1):9-20. (Pubitemid 32201865)
14. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249-1259.
15. Lowenberg B, Ossenkoppele GJ, Van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235-1248.
16. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649. (Pubitemid 46594039)
17. Bennett JM, Young ML, Andersen JW, et al. Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience. Cancer. 1997;80(11 suppl):2205-2209. (Pubitemid 27509592)
18. Buchner T, Hiddemann W, Berdel WE, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol. 2003;21(24):4496-4504. (Pubitemid 46603514)
19. Creutzig U, Ritter J, Zimmermann M, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia. 2001;15(3):348-354. (Pubitemid 32243767)
20. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol. 2010;28(5):808-814.
21. Ohtake S, Miyawaki S, Fujita H, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood. 2011;117(8):2358-2365.
22. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331(14):896-890.
23. Büchner T, Krug U, Berdel WE, et al. Maintenance for acute myeloid leukemia revisited. Curr Treat Options Oncol. 2007;8(4):296-304.
24. Krug U, Lübbert M, Büchner T. Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest? Curr Opin Hematol. 2010;17(2):85-90.